Intervention not reported
Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events the resulted in discontinuation of treatment · adults and children with confirmed clinical and parasitological P vivax malaria
It is very uncertain whether the intervention changes adverse events the resulted in discontinuation of treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events that result in the discontinuation of treatment · adults and children with confirmed clinical and parasitological P vivax malaria
It is very uncertain whether the intervention changes adverse events that result in the discontinuation of treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events that result in the discontinuation of treatment · adults and children with confirmed clinical and parasitological P vivax malaria
It is very uncertain whether the intervention changes adverse events that result in the discontinuation of treatment (very low certainty).
1 finding from 1 review
Safety outcomes: drug discontinuation · adults with HIV and progressive disseminated histoplasmosis
It is very uncertain whether induction: liposomal amphotericin changes safety outcomes: drug discontinuation compared with amphotericin deoxycholate (very low certainty).
1 finding from 1 review
Linezolid discontinuationl · drug‐resistant pulmonary tuberculosis
1 finding from 1 review
Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis
It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).
1 finding from 1 review
Treatment discontinuation · HIV‐positive people
Antifungal prophylaxis showed no clear difference in treatment discontinuation compared with no antifungal prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to treatment discontinuation ( · adults and adolescents with pleural TB
The intervention may leads to higher adverse events leading to treatment discontinuation ( (low certainty).
1 finding from 1 review
Discontinuation of treatment due to side effects ( · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine showed no clear difference in discontinuations due to adverse effects compared with doxycycline; GRADE not reported.
1 finding from 1 review
Discontinuation of medication due to adverse events · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher discontinuation of drug due to adverse effects compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Intervention not reported
Discontinuation rate · antiretroviral‐naïve individuals
The intervention showed no clear difference in discontinuation rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes adverse events leading to discontinuation of treatment compared with beta‐lactams (very low certainty).
1 finding from 1 review